June 12th, 2024 (Shanghai) — We are glad to announce that Marco Cerato, the Executive Vice President of Glenmark Pharmaceuticals, has been invited to present at ACCESS CHINA Partnering Forum@CPHI on June 19th.
About ACCESS CHINA Partnering Forum @ CPHI
ACCESS CHINA Partnering Forum @ CPHI focus on core topics such as pharmaceutical production, distribution, and international cooperation. Interested companies are welcome to sign up.
Time：June 19th, 2024
Organizers: IM Sinoexpo, YAFO Capital
Location：Meeting Room M34, Hall E6 (Shanghai New International Expo Centre, Pudong)
Registration:
Agenda:
About the speaker
Marco Cerato is a Pharma and Biotech professional with close to two decades of proven track record in leading Global Business and Corporate Development, Alliance management, Portfolio management, Marketing and Medical Affairs teams in small to mid size companies. Marco holds a degree in Industrial Biotechnologies, a specialisation in Processes and products, a Master in Marketing and Communication and an executive MBA from Bocconi University.
Marco’s career started in the lab with a quick transition to the Strategic analysis and commercial controlling dept of Eurand, he then took over roles of increasing responsibility in Adare and Helsinn Healthcare up to heading Global Corporate and Business Development teams. In 2018, he moved to Mundipharma to become the first global head of corporate and business development ever appointed in such organization.
Since March 2021, Marco has joined Glenmark Pharmaceuticals and he has taken up a role as global head of Business Development, Alliance management, and Portfolio management. Recently his group has expanded to include Global Marketing and Branding and Medical Affairs aiming to build a full fledged innovation driven organization.”
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is a research‐led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus in the therapy areas of Respiratory, Dermatology and Oncology. The company has four research and development centres, ten world‐class manufacturing facilities spread across five continents, and operations in over eighty countries.
In its quest to be among the first few Indian pharmaceutical companies to develop an innovative drug for the world, Glenmark is treading two parallel paths. One pursues the discovery of a novel chemical or biological entity. The second that leads towards scaling the value chain by creating specialty products, like RYALTRIS®, that address gaps in treatment.
Glenmark Pharmaceuticals and its fully owned US subsidiary Ichnos Sciences together have formed an alliance ‘Ichnos Glenmark Innovation’ to use different modalities, technologies and combined expertise to treat cancer. It has a robust pipeline of innovative molecules, in various stages of clinical development across oncology and immunology.
Glenmark is driven by a continuous commitment to create ‘A New Way for a New World’. Harnessing the potential of their core strengths of innovation, research, and scientific knowledge, they remain determined to consistently challenge established treatment paradigms. It allows them to identify and deliver promising solutions that make a considerable difference to the lives of patients in diverse geographies.
Contact US
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 